Royalty Pharma plc financial data

Symbol
RPRX on Nasdaq
Location
110 East 59 Th Street, New York, NY
State of incorporation
United Kingdom
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 417 % +51.3%
Return On Equity 11.5 % +502%
Return On Assets 6.72 % +509%
Operating Margin 68.1 % +299%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 13.7B USD -25.9%
Weighted Average Number of Shares Outstanding, Basic 448M shares -0.18%
Weighted Average Number of Shares Outstanding, Diluted 593M shares -1.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.27B USD -2.51%
Research and Development Expense 2M USD -98%
General and Administrative Expense 228M USD -13.5%
Costs and Expenses 722M USD -62.5%
Operating Income (Loss) 1.54B USD +289%
Nonoperating Income (Expense) 170M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 1.71B USD +360%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent 1.15B USD +521%
Earnings Per Share, Basic 2.57 USD/shares +559%
Earnings Per Share, Diluted 2.56 USD/shares +574%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 950M USD +1.45%
Other Assets, Current 4.97M USD -26.8%
Assets, Current 1.79B USD +3.79%
Other Assets, Noncurrent 42.8M USD +112%
Assets 18B USD +13.8%
Liabilities, Current 1.17B USD +813%
Other Liabilities, Noncurrent 5.58M USD
Liabilities 7.78B USD +24.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD -100%
Retained Earnings (Accumulated Deficit) 2.76B USD +29.5%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 10.3B USD +7.03%
Liabilities and Equity 18B USD +13.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 665M USD -35.7%
Net Cash Provided by (Used in) Financing Activities -212M USD -0.77%
Net Cash Provided by (Used in) Investing Activities -86.7M USD +84.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 366M USD +38.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 950M USD +1.45%
Interest Paid, Excluding Capitalized Interest, Operating Activities 79M USD -4.38%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 1.13B USD +4401%
Additional Paid in Capital 4.11B USD +2.52%
Amortization of Intangible Assets 0 USD -100%
Share-based Payment Arrangement, Expense 2.9M USD -22.2%
Interest Expense 184M USD -1.8%